InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,815.03
(
0.61%
)
US TECH 100
19,759.20
(
0.13%
)
Dow Jones
42,863.86
(
0.97%
)
Brent Oil
77.58
(
0.14%
)
Bitcoin
64,388.17
(
2.45%
)
Post# of 648882
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Tuff-Stuff

Send PM Follow Ignore
Followers 218
Posts 247348
Boards Moderated 2
Alias Born 04/06/2006

Tuff-Stuff

Re: Tuff-Stuff post# 311742

Monday, 04/12/2010 8:59:44 AM

Monday, April 12, 2010 8:59:44 AM

Post# of 648882
RPC>>Roberts Pharm monetizing China-Based Jade pharmaceutical division : Co announced it anticipates prospective purchasers or financiers will complete due diligence for RPC's China-based subsidiary Jade Pharmaceutical, Inc. ("JPI") by the end of May 2010. RPC expects JPI will be contractually positioned to move forward with the completion of a sale or financing by the end of the third quarter 2010. RPC currently owns approximately 98% of JPI, which as part of RPC's deconsolidation process, is noted as a special asset on RPC's balance sheet and valued at approximately US$20 million as of September 30, 2009.

Your World Is As BIG as You Make It!!!

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up